JP2022519721A5 - - Google Patents

Info

Publication number
JP2022519721A5
JP2022519721A5 JP2021546285A JP2021546285A JP2022519721A5 JP 2022519721 A5 JP2022519721 A5 JP 2022519721A5 JP 2021546285 A JP2021546285 A JP 2021546285A JP 2021546285 A JP2021546285 A JP 2021546285A JP 2022519721 A5 JP2022519721 A5 JP 2022519721A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
hypnotic
muscle relaxant
nri
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2021546285A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022519721A (ja
JP7705348B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/017323 external-priority patent/WO2020163785A1/en
Publication of JP2022519721A publication Critical patent/JP2022519721A/ja
Publication of JP2022519721A5 publication Critical patent/JP2022519721A5/ja
Priority to JP2025016270A priority Critical patent/JP2025084754A/ja
Application granted granted Critical
Publication of JP7705348B2 publication Critical patent/JP7705348B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2021546285A 2019-02-08 2020-02-07 睡眠時無呼吸を治療するための方法および組成物 Active JP7705348B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025016270A JP2025084754A (ja) 2019-02-08 2025-02-03 睡眠時無呼吸を治療するための方法および組成物

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962803223P 2019-02-08 2019-02-08
US62/803,223 2019-02-08
PCT/US2020/017323 WO2020163785A1 (en) 2019-02-08 2020-02-07 Methods and compositions for treating sleep apnea

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025016270A Division JP2025084754A (ja) 2019-02-08 2025-02-03 睡眠時無呼吸を治療するための方法および組成物

Publications (3)

Publication Number Publication Date
JP2022519721A JP2022519721A (ja) 2022-03-24
JP2022519721A5 true JP2022519721A5 (https=) 2023-02-15
JP7705348B2 JP7705348B2 (ja) 2025-07-09

Family

ID=71947080

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021546285A Active JP7705348B2 (ja) 2019-02-08 2020-02-07 睡眠時無呼吸を治療するための方法および組成物
JP2025016270A Pending JP2025084754A (ja) 2019-02-08 2025-02-03 睡眠時無呼吸を治療するための方法および組成物

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025016270A Pending JP2025084754A (ja) 2019-02-08 2025-02-03 睡眠時無呼吸を治療するための方法および組成物

Country Status (17)

Country Link
US (1) US12558327B2 (https=)
EP (2) EP3920898B1 (https=)
JP (2) JP7705348B2 (https=)
KR (1) KR20210125507A (https=)
CN (2) CN118557736A (https=)
AU (2) AU2020219809B2 (https=)
BR (1) BR112021015600A2 (https=)
CA (1) CA3129270A1 (https=)
EA (1) EA202192202A1 (https=)
ES (1) ES3049086T3 (https=)
IL (1) IL285197A (https=)
MX (2) MX2021009407A (https=)
MY (1) MY210043A (https=)
PH (1) PH12021551850A1 (https=)
SG (1) SG11202108225QA (https=)
UA (1) UA130366C2 (https=)
WO (1) WO2020163785A1 (https=)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102874891B1 (ko) 2018-01-30 2025-10-21 애프니메드, 인코포레이티드 (델라웨어) 수면 무호흡증을 치료하기 위한 방법 및 조성물
CN118557736A (zh) 2019-02-08 2024-08-30 布里格姆妇女医院 用于治疗睡眠呼吸暂停的方法和组合物
WO2022204228A1 (en) * 2021-03-24 2022-09-29 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
US20240277719A1 (en) * 2021-06-17 2024-08-22 Apnimed, Inc. (Delaware) Norepinephrine reuptake inhibitors for treating sleep apnea
EP4522149A1 (en) * 2022-05-13 2025-03-19 Apnimed, Inc. (Delaware) Methods and compositions for treating sleep apnea
KR20250057804A (ko) * 2022-09-02 2025-04-29 애프니메드, 인코포레이티드 (델라웨어) 수면 무호흡증을 치료하기 위한 방법 및 조성물

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
AU767877B2 (en) 1999-05-20 2003-11-27 Sepracor, Inc. Methods for treatment of asthma using S-oxybutynin
PT1257277E (pt) 2000-02-24 2005-09-30 Pharmacia & Upjohn Co Llc Novas combinacoes de farmacos
US20020155113A1 (en) 2001-03-13 2002-10-24 Miyoung Chun Methods for treating or preventing cardiovascular disorders by modulating metalloprotease function
US20030185882A1 (en) 2001-11-06 2003-10-02 Vergez Juan A. Pharmaceutical compositions containing oxybutynin
US20040235925A1 (en) 2002-12-17 2004-11-25 Pharmacia Corporation Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof
US20070219201A1 (en) 2004-05-27 2007-09-20 Warner-Lambert Company Llc Combination of atomoxetine and a 5ht1a receptor agonist for treating adhd and other disorders
US20060039866A1 (en) 2004-08-20 2006-02-23 Cypress Bioscience, Inc. Method for treating sleep-related breathing disorders
US8252321B2 (en) 2004-09-13 2012-08-28 Chrono Therapeutics, Inc. Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like
EP1827450A4 (en) * 2004-11-17 2009-04-22 Cypress Bioscience Inc METHOD FOR REDUCING THE SIDE EFFECTS OF TREATMENT WITH MIRTAZAPINE
CN101132777A (zh) 2004-12-20 2008-02-27 科利吉姆制药公司 用于睡眠障碍的药物组合物
FR2889811B1 (fr) 2005-08-19 2009-10-09 Sanofi Aventis Sa Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique.
PL2083811T3 (pl) 2006-11-22 2017-05-31 Clinical Research Associates, Llc Sposoby leczenia zespołu downa, zespołu łamliwego chromosomu x oraz autyzmu
WO2008122019A1 (en) 2007-04-02 2008-10-09 Cypress Biosciences, Inc. Improving the tolerability of both mirtazapine and reboxetine by using them in combination
EP2142183A2 (en) * 2007-04-09 2010-01-13 Sepracor Inc. Methods and compositions comprising desvenlafaxine or duloxetine for treating sleep-related breathing disorders
EP2167096A4 (en) * 2007-06-13 2010-07-14 Cypress Bioscience Inc IMPROVING TOLERANCE TO MIRTAZAPINE AND A SECOND ACTIVE INGREDIENT BY THE COMBINED USE OF THEM
AR069875A1 (es) 2007-12-21 2010-02-24 Eurand Inc Composiciones de temazepam para tabletas de desintegracion oral y metodo de preparacion
US20100204058A1 (en) 2009-01-28 2010-08-12 Howard Yuan-Hao Chang Profiling for Determination of Response to Treatment for Inflammatory Disease
JP2014503593A (ja) 2011-01-28 2014-02-13 ファンタスティック・メディカル・リサーチ・インスティテュート・エルエルシー 閉塞性睡眠時無呼吸を処置するための方法
US20170304286A1 (en) 2014-10-24 2017-10-26 Launx Biomedical Co., Ltd. New indication of paroxetine pharmaceutical composition for treating cancer
MX373319B (es) * 2015-04-27 2020-06-13 Arena Pharm Inc Derivados de hexahidro-[1-4]diazepino[6,7,1-hi]indol-8-carboxamida como agonistas del receptor 5-ht2c y el uso de los mismos en el tratamiento de enfermedades relacionadas con dicho receptor.
US10022355B2 (en) 2015-06-12 2018-07-17 Axovant Sciences Gmbh Diaryl and arylheteroaryl urea derivatives as modulators of the 5-HT2A serotonin receptor useful for the prophylaxis and treatment of REM sleep behavior disorder
ES2925951T3 (es) * 2015-07-22 2022-10-20 John Hsu Composición que comprende un agente terapéutico y un estimulante respiratorio y métodos para su uso
GEAP202416602A (en) 2017-04-28 2024-10-10 Brigham & Womens Hospital Inc Methods and compositions for treating sleep apnea
KR102874891B1 (ko) 2018-01-30 2025-10-21 애프니메드, 인코포레이티드 (델라웨어) 수면 무호흡증을 치료하기 위한 방법 및 조성물
CN118557736A (zh) 2019-02-08 2024-08-30 布里格姆妇女医院 用于治疗睡眠呼吸暂停的方法和组合物

Similar Documents

Publication Publication Date Title
JP2022519721A5 (https=)
JP6824314B2 (ja) アカンプロサート製剤、それを用いる方法、およびそれを含む合剤
EP2148670B1 (en) Titration of tapentadol
US20250177385A1 (en) Combinations comprising brexpiprazole or a salt thereof and a second drug for use in the treatment of a cns disorder
JP5241228B2 (ja) 非ステロイド性抗炎症薬、鬱血除去薬および鎮静作用の少ない抗ヒスタミン薬を含む多層錠
JP2025084754A5 (https=)
US20090023744A1 (en) Combination therapy for depression
CN106413717A (zh) 药物组合物
CA2929909C (en) Hydromorphone and naloxone for treatment of pain and opioid bowel dysfunction syndrome
TW202317101A (zh) 治療抑鬱狀態之方法
JP2020533415A (ja) ナルコレプシーの処置におけるガボキサドールの使用
JP2022506113A5 (https=)
CN104379138B (zh) 阿坎酸制剂、其使用方法及包含阿坎酸制剂的组合
US20090035370A1 (en) Dosage form and method of use
TW202228660A (zh) 經口投予製劑
HK1233916A1 (en) Titration of tapentadol
HK1140940B (en) Titration of tapentadol
HK40021402A (en) Combinations comprising brexpiprazole or a salt thereof and a second drug for use in the treatment of a cns disorder